A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region

Launched by ASTRAZENECA · Jul 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying patients with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL), which is an aggressive form of non-Hodgkin lymphoma. The goal is to better understand the characteristics of patients in the Middle East and Africa, how they are being treated, and their access to new and emerging therapies. The study will include patients who are either starting treatment for the first time or those whose disease has returned or not responded to previous treatments.

To join the study, patients must be 18 years or older with a confirmed diagnosis of DLBCL. Participants will be asked to share information about their health, the treatments they receive, and their experiences with new therapies. This study does not involve testing new treatments but looks at real-world care to help improve future treatment options. If you or a loved one fits these criteria and is interested, the study team will explain everything in detail before any participation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female patients aged 18 years or older at diagnosis.
• • 2. Patients who have confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) according to the investigator's decision and/or histopathological diagnosis.
• • 3. For Cohort 1: DLBCL patients who are eligible to start treatment\* according to the investigator's decision.
• • 4. For Cohort 2: patients who are diagnosed with DLBCL and have failed at least one prior line of therapy.
• • 5. Patients willing to sign the written informed consent form (ICF) indicating that they understand the purpose of the study and procedures required for participation.
• Exclusion Criteria:
• • 1. Patients who are not eligible for treatment for any reason, according to the investigator's judgment and decision
• • 2. Patients with concurrent active malignancies other than DLBCL.
• • 3. Patients who are actively participating in any other clinical trial.